Nurami Medical Achieves Significant Milestones for Artifix® Dural Repair Graft Development

Nurami Medical, a pioneering company specializing in regenerative solutions for soft tissue repair, recently announced its successful completion of crucial Phase 1 milestones under an EIC-backed grant for its innovative product, Artifix®. This synthetic, biomimetic dural repair adhesive patch is poised to become a game-changer in the field of neurosurgical repair.

During the initial phase of development, Nurami achieved several key objectives including the completion of preclinical testing, the submission of technical documentation to European Union regulators, and the approval of initial trial countries. These achievements signal a significant advancement towards obtaining First-in-Human (FiH) clinical trial approvals, which are expected by the end of 2025. Following the approvals, the kickoff for clinical trials is anticipated shortly thereafter.

Dr. Amir Bahar, Chief Commercial Officer and co-founder of Nurami, expressed the company's enthusiasm about the progress made. He stated, "Successfully completing these key milestones marks a major step in bringing Artifix® to clinical use. This product builds on our proprietary platform and underscores our commitment to driving innovation within neurosurgical repair."

Furthermore, Nurami has initiated preliminary marketing efforts and clinical engagement activities. The team is actively engaging leading neurosurgical Key Opinion Leaders (KOLs) throughout Europe and the United States, alongside participating in international neurosurgical conferences. These efforts are designed to enhance awareness of the product and gather valuable feedback from experts in the field, thus strengthening the product's market presence.

In recognition of its accomplishments, Nurami has successfully secured Phase 2 funding from the esteemed European Innovation Council (EIC). The company expresses deep gratitude for the continued support and endorsement from the EIC, acknowledging the vital role it plays in propelling Nurami's vision and capabilities forward.

As part of its expanding portfolio, Nurami has commenced preliminary sales of ArtiFascia®, its first product that received FDA clearance. This sutureable synthetic dural repair graft integrates advanced bioengineered polymers and marks a critical commercial milestone for the organization.

Nora Nseir, Nurami's CEO and co-founder, emphasized the importance of this support, stating, "We deeply value the EIC's partnership and the trust of our investors. Their support accelerates our mission to deliver innovative, clinically impactful solutions that improve surgical outcomes and enhance patients' lives."

Founded in Haifa, Israel, Nurami Medical is dedicated to advancing the field of soft tissue repair through innovative bioengineered materials. Its proprietary technology platform cleverly combines non-biological polymers with nanofiber structures, promoting healing and facilitating ease of surgical use.

With both ArtiFascia® and the forthcoming Artifix® in its product lineup, Nurami Medical is cementing its position at the forefront of surgical innovation, ready to address the unmet needs within surgical disciplines. Stay tuned for more updates as Nurami moves forward on its journey towards improving the effectiveness of surgical repairs and enhancing patient care.

For more information about Nurami Medical and its pioneering solutions, visit Nurami Medical's Website.